Skip to main content

Market Overview

The Daily Biotech Pulse: Exelixis Signs Cancer Drug Licensing Deal, Adamis Offering, Surmodics Surges On Earnings

The Daily Biotech Pulse: Exelixis Signs Cancer Drug Licensing Deal, Adamis Offering, Surmodics Surges On Earnings

Here's a roundup of top developments in the biotech space over the last 24 hours.

Scaling The Peaks

(Biotech stocks hitting 52-week highs on Aug. 1)

  • Grifols SA - ADR ADR Class B (NASDAQ: GRFS)
  • Odonate Therapeutics Inc (NASDAQ: ODT)
  • ZIOPHARM Oncology Inc. (NASDAQ: ZIOP)

Down In The Dumps

(Biotech stocks hitting 52-week lows on Aug. 1)

  • Abeona Therapeutics Inc (NASDAQ: ABEO)
  • Aclaris Therapeutics Inc (NASDAQ: ACRS)
  • Alimera Sciences Inc (NASDAQ: ALIM)
  • Aquestive Therapeutics Inc (NASDAQ: AQST)
  • Atreca Inc (NASDAQ: BCEL)
  • China SXT Pharmaceuticals Inc (NASDAQ: SXTC)
  • Equillium Inc (NASDAQ: EQ)
  • Evelo Biosciences Inc (NASDAQ: EVLO)
  • Gamida Cell Ltd (NASDAQ: GMDA)
  • Hemispherx BioPharma, Inc (NYSE: HEB)
  • Intercept Pharmaceuticals Inc (NASDAQ: ICPT)
  • Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX)(reported below-consensus Q2 results)
  • Ligand Pharmaceuticals Inc. (NASDAQ: LGND)
  • Mediwound Ltd (NASDAQ: MDWD)
  • Neurometrix Inc (NASDAQ: NURO)
  • Oncolytics Biotech, Inc. (NASDAQ: ONCY)
  • OptiNose Inc (NASDAQ: OPTN)
  • T2 Biosystems Inc (NASDAQ: TTOO)(reacted to negative second-quarter results)

See Also: Biotech Stock On The Radar: Veru, A Catalyst-Rich Biopharma

Stocks In Focus

Exelixis Strikes Option and Licensing Agreement For Developing Cancer Drugs

Exelixis, Inc. (NASDAQ: EXEL) has entered into an exclusive collaboration, option and license agreement with India-based biotech Aurigene Discovery Technologies Limited to in-license as many as six programs from the latter. Aurigene is a wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd (NYSE: RDY) and is engaged in the development of therapies for cancer and inflammatory diseases.

Under the agreement, Exelixis will pay Aurigene an upfront payment of $10 million for exclusive options to license three preexisting programs. Also, both companies plan to initiate three Aurigene-led drug discovery programs for additional option payments of $2.5 million per program.

Exelixis shares moved up 0.99% to $21.48 in after-hours trading.

Pfizer, Glaxo Consummate Merger of Consumer Healthcare JV

Pfizer Inc. (NYSE: PFE) and GlaxoSmithKline plc (NYSE: GSK) said the merger of the companies' consumer health care businesses is now complete, creating the world's largest OTC business. Pfizer owns 32% equity stake in the venture and Glaxo the remaining 68%.

The combined business, which will operate globally as GSK Consumer Healthcare, is to be led by Glaxo CEO Brian McNamara.

Adaptive's clonoSEQ Test Approved In New York State For Monitoring Blood Cancers

Adaptive Biotechnologies Corp (NASDAQ: ADPT) said the State of New York Clinical Laboratory Evaluation Program has approved the clonoSEQ Assay or the detection and monitoring of minimal residual disease in patients with B-cell blood cancers.

"The CLEP approval makes clonoSEQ testing accessible to patients in New York who have been diagnosed with B-cell cancers, a subset of lymphoid cancers that includes ALL, multiple myeloma, chronic lymphocytic leukemia and B-cell non-Hodgkin's lymphoma," the company said.

The stock rose 2.44% to $39.49 in after-hours trading.

Adamis to Offer Shares and Warrants

Adamis Pharmaceuticals Corp (NASDAQ: ADMP) said it intends to sell shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering.

The stock plunged 16.52% to 92 cents in after-hours trading.


SurModics, Inc. (NASDAQ: SRDX)'s third-quarter revenues climbed 9.5% year-over-year to $24.3 million. The EPS, on a non-GAAP basis, fell from 20 cents to 11 cents. The company raised its guidance for 2019.

The stock rallied 13.67% to $41.70 in after-hours trading.

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) reported second-quarter net product sales of $83.2 million, up 46% year-over-year, and its net loss narrowed from 51 cents per share to 38 cents per share. The company raised its 2019 net product sales guidance.

The stock added 6.59% to $26.20 in after-hours trading.

Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) said its second-quarter net product sales climbed 24% to $59.1 million. The EPS increased year-over-year from 15 cents to 28 cents. The company reiterated its 2019 net product sales guidance and also its year-end cash guidance.

The stock gained 7.31% to $13.36 in after-hours trading.

On The Radar


Akorn, Inc. (NASDAQ: AKRX) (before the market open)
ABIOMED, Inc. (NASDAQ: ABMD) (before the market open)
Agios Pharmaceuticals Inc (NASDAQ: AGIOv (before the market open)
Clovis Oncology Inc (NASDAQ: CLVS) (before the market open)
Concert Pharmaceuticals Inc (NASDAQ: CNCE) (before the market open)
Syros Pharmaceuticals Inc (NASDAQ: SYRS) (before the market open)
Insmed Incorporated (NASDAQ: INSM) (before the market open)
Intellia Therapeutics Inc (NASDAQ: NTLA) (before the market open)
Genomic Health, Inc. (NASDAQ: GHDX) (after the market close)
Acorda Therapeutics Inc (NASDAQ: ACOR) (after the market close)
Emergent Biosolutions Inc (NYSE: EBS) (after the market close)
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) (after the market close)
Coherus Biosciences Inc (NASDAQ: CHRS) (after the market close)
Kindred Biosciences Inc (NASDAQ: KIN) (after the market close)
Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO) (after the market close)
Geron Corporation (NASDAQ: GERN) (after the market close)
Corvus Pharmaceuticals Inc (NASDAQ: CRVS) (after the market close)
CareDx Inc (NASDAQ: CDNA) (after the market close)
Globus Medical Inc (NYSE: GMED) (after the market close)
Verastem Inc (NASDAQ: VSTM) (after the market close)
• Ultragenyx (after the market close)
Kura Oncology Inc (NASDAQ: KURA) (after the market close)


Related Articles (XBI + IBB)

View Comments and Join the Discussion!

Posted-In: Biotech M&A News Offerings Contracts Top Stories Pre-Market Outlook Trading Ideas Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at